Scinai ImmunotherapeuticsSCNI
Market Cap: $3.05M
About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
Employees: 31
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.03% less ownership
Funds ownership: 0.03% [Q1] → 0% (-0.03%) [Q2]
31% less funds holding
Funds holding: 13 [Q1] → 9 (-4) [Q2]
74% less capital invested
Capital invested by funds: $214K [Q1] → $54.7K (-$159K) [Q2]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 8
Research analyst outlook
We haven’t received any recent analyst ratings for SCNI.
Financial journalist opinion
Based on 4 articles about SCNI published over the past 30 days